Keywords: promising, ph, ii, data, abbott, abt-874, results
Promising Ph II data for Abbott's ABT-874
Article | 22 November 2004
Results reported in the New England Journal of Medicine suggest that Abbot Laboratories' ABT-874, a fully-human anti-interleukin-12 monoclonal antibody, may ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
